Exencial Wealth Advisors LLC Purchases 390 Shares of Gilead Sciences, Inc. $GILD

Exencial Wealth Advisors LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.7% during the 2nd quarter, Holdings Channel reports. The fund owned 3,470 shares of the biopharmaceutical company’s stock after buying an additional 390 shares during the period. Exencial Wealth Advisors LLC’s holdings in Gilead Sciences were worth $385,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in GILD. Price T Rowe Associates Inc. MD boosted its holdings in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after acquiring an additional 11,156,382 shares in the last quarter. Nuveen LLC bought a new position in Gilead Sciences in the first quarter worth approximately $620,415,000. Kingstone Capital Partners Texas LLC bought a new position in Gilead Sciences in the second quarter worth approximately $238,083,000. Los Angeles Capital Management LLC boosted its holdings in Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after acquiring an additional 2,040,261 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after acquiring an additional 1,942,433 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on GILD. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a report on Friday, July 25th. BMO Capital Markets raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a report on Monday, October 20th. Rothschild & Co Redburn raised their target price on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. Cantor Fitzgerald raised their target price on Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Finally, Royal Bank Of Canada raised their target price on Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $122.61.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $120.94 on Friday. The business’s fifty day simple moving average is $115.47 and its 200 day simple moving average is $111.01. The firm has a market capitalization of $150.06 billion, a P/E ratio of 24.09, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $124.61. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares in the company, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,500 shares of company stock worth $8,281,540. 0.27% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.